ABT vs JBGS · P/E 25, rev $44.33B vs rev $257.0M
Abbott Laboratories (ABT) versus JBG SMITH Properties (JBGS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
JBG SMITH Properties (JBGS) is a reit - office company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported JBGS revenue for 2026-06-30 was $257.0M. Net income was -$77.9M. JBGS currently screens at market cap $1.31B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. JBGS currently screens at market cap $1.31B.
Not investment advice. Open the ABT and JBGS stock pages for the full models.
Not investment advice.